Stocks Valuation of Johnson & Johnson (J&J): Analysis of Ongoing Risks of Pharmaceuticals Corporations in Post-Pandemic Era

Xintong Wang

doi:10.54097/hbem.v1i.2315

Authors

Xintong Wang

DOI:

https://doi.org/10.54097/hbem.v1i.2315

Keywords:

Johnson & Johnson; Business Development; COVID-19; Pharmaceutical Industry's Business Threats; Stock Valuation.

Abstract

The global COVID-19 pandemic increased public awareness of healthcare and provided development chances for pharmaceutical corporations. This paper focuses on investigating and presenting SWOT-Analysis to evaluate the competitiveness of Johnson & Johnson in the pharmaceutical industry. Moreover, the strengths, weaknesses, opportunities, and threats will be analyzed as well. It is found that risks will compound with the challenges of the pharmaceutical industry. However, it also means that the pharmaceutical industry is at a time of opportunities due to the public increasing awareness and demand for healthcare and medicine. Through this analysis, it will provide insight to the pharmaceutical industry's business threats in the post-pandemic era. Moreover, a guidance and proposes possible solutions to businesses that are at risk during the post-pandemic era.

Downloads

Download data is not yet available.

References

3rd Quarter 2020 Earnings Call. Johnson & Johnson Quarterly Results. (2020, October 13). Retrieved September 11, 2022, from https://johnsonandjohnson.gcs-web.com/.

Flynn, S. (2021, May 13). Six major risks facing pharmaceutical manufacturers in 2021. European Pharmaceutical Review. Retrieved September 11, 2022, from https:// www. European pharmaceutical review. com/ article/153871/six-major-risks-facing-pharmaceutical-manufacturers-in-2021/.

Griffin, R., & Feeley, J. (2022, August 11). J&J to halt talc baby powder implicated in Cancer Litigation (JNJ). Bloomberg.com. Retrieved September 11, 2022, from https:// www. Bloomberg. com/news/ articles/ 2022-08-11/j-j-to-halt-talc-baby-powder-implicated-in-cancer-litigation.

Johnson & Johnson (JNJ) - market capitalization. CompaniesMarketCap.com - companies ranked by market capitalization. (2022). Retrieved September 11, 2022, from https:// companies market cap. com/ johnson-and-johnson/marketcap/.

Johnson & Johnson 2021 Annual Report. 2022 Annual Meeting Materials. (2022). Retrieved September 11, 2022, from https://www.investor.jnj.com/annual-meeting-materials/2021-annual-report.

Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business. Johnson&Johnson. (2021, November 12). Retrieved September 11, 2022, from https://www.jnj.com/johnson-johnson-announces-plans-to-accelerate-innovation-serve-patients-and-consumers-and-unlock-value-through-intent-to-separate-consumer-health-business.

Johnson & Johnson SEC registration. SEC.report. (2022). Retrieved September 11, 2022, from https:// sec. report/CIK/0000200406.

Pfizer's financial performance in 2021. Pfizer's financial performance in 2021 | Pfizer 2021 Annual Report. (2021). Retrieved September 11, 2022, from https:// www.pfizer. com/sites/ default/ files/investors/ financial_ reports/annual_reports/2021/performance/.

PricewaterhouseCoopers. (n.d.). Pharma 2020: From vision to decision. About the Pharma 2020 series. Retrieved September 11, 2022, from https://pwc.to/3aVjYFD.

Reuter, E. (2022, July 19). J&J lowers full-year sales forecast amid rising inflation, currency pressures. MedTech Dive. Retrieved September 11, 2022, from https://www.medtechdive.com/news/johnson-johnson-earnings-currency-pressures-medtech-rebound/627589/.

Rothman, L. A. (2022, July 18). Johnson & Johnson's (JNJ) 3 most profitable lines of business. Investopedia. Retrieved September 11, 2022, from https:// www. investopedia. com/articles/ markets/ 020316/ johnson-johnsons-3-most-profitable-lines-business-jnj.asp.

Sagonowsky, E., Dunleavy, K., & Kansteiner, F. (2022, March 8). The top 10 drugs losing us exclusivity in 2022. Fierce Pharma. Retrieved September 11, 2022, from https://www.fiercepharma.com/special-reports/top-10-drugs-losing-us-exclusivity-2022.

Sales of Key Products/Franchises_Q1. Quarterly Results. (2022). Retrieved September 11, 2022, from https: // johnsonandjohnson.gcs-web.com/.

Taylor, P. (2022, July 11). NICE makes J&J’s Tremfya more accessible in England and Wales. pharmaphorum. Retrieved September 11, 2022, from https://pharmaphorum.com/news/nice-makes-jjs-tremfya-more-accessible-in-england-and-wales/.